Global Brain has invested in EditForce, Inc. (EditForce), a company developing unique DNA / RNA editing technology to bring innovation to various industries, through its GB-VII Growth Fund Investment Limited Partnership (GB-VII) and its KDDI Open Innovation Fund III (KOIF III). EditForce has developed DNA/RNA editing tools by integrating pentatricopeptide repeat (PPR) proteins with various enzymes. As opposed to other genome editing technology, this technology enables the editing of not only DNA sequences but also RNA sequences. Currently, EditForce has focused on the field of pharmaceuticals and has grown through business alliances with multiple pharmaceutical companies. Global Brain has decided to invest in EditForce, thinking highly of their unique DNA / RNA editing technology and strong management team. Global Brain will continue leveraging its resources to assist EditForce in fast-growing on the field of pharmaceuticals and expanding their business into new field such as agriculture and chemical. ## About EditForce, Inc.

Location: 4F Fukuoka Tenjin Fukoku Seimei Bldg. 1-9-17, Tenjin, Chuo-ku, Fukuoka

Representative: Takashi Ono

Founded: May 15, 2015

URL: https://www.editforce.co.jp/

## About GB-VII

Name: GB-VII Growth Fund Investment Limited Partnership

General Partner: Global Brain Corporation

## About KOIF III

Name: KDDI Open Innovation Fund III

General Partner: Global Brain Corporation

Fund Size: 20 Billion JPY

## About Global Brain

Location: Tokyo, Japan

Representative: Yasuhiko Yurimoto

Founded: January, 1998

URL: https://globalbrains.com/

Global Brain has invested in EditForce, Inc., a company developing unique DNA / RNA editing technology